

Anti-IL-2Ra/CD25 Antibody (Daclizumab)

Introduction

Daclizumab (Zenapax) is a humanized monoclonal antibody that blocks CD25, the alpha subunit of the high-affinity interleukin-2 receptor (IL-2R- α). Daclizumab (Zenapax) reversibly binds to CD25 and blocks the interaction of IL-2 with IL-2R- α . Daclizumab (Zenapax) can be used in multiple sclerosis research.

Product parameters

Alternative Names	Zenapax, Zinbryta, dacliximab
Target Accession	P01589
Target	IL-2Ra / CD25
CAS number	152923-56-3
Molecular Weight	144.12 kDa
Host	CHO
Reactivity	Human, Mouse, Rat, Rhesus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 2R α His at 2 ug/mL can bind Anti-IL-2Ra/CD25 Antibody (Daclizumab), EC50=0.002707 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

